publication date: May. 15, 2015

Sotomayor Named Inaugural Director of GW Cancer Center

 

EDUARDO SOTOMAYOR was named inaugural director of the GW Cancer Center. He will also serve as a professor of medicine.

Sotomayor will serve as chief academic and clinical leader with responsibility and authority over all aspects of the GWCC, starting in July. The GWCC will incorporate all cancer-related activities, as well as serve as the platform for future development. One of his top priorities will be to attain NCI designation within the decade.

Prior to joining GWCC, Sotomayor served as the scientific director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. He also served as the Susan and John Sykes Endowed Chair of Hematologic Malignancies and chair of the Department of Malignant Hematology at the Moffitt Cancer Center and Research Institute, as well as professor in the Department of Oncologic Sciences and the Department of Pathology and Cell Biology at the University of South Florida College of Medicine.

His primary area of research is immunobiology and immunotherapy of B-cell malignancies, with emphasis on the design of novel immunotherapeutic approaches for these diseases. Clinically, Sotomayor has a particular interest in mantle cell lymphoma.

He has received the Lymphoma Research Foundation Fellowship Award and Junior Faculty Award, the Celgene’s Young Investigator Achievement Award in Hematology, as well as continued research project grant funding during the past 15 years from NIH to support his basic and translational studies in cancer immunology and immunotherapy.

Sotomayor is a member of several committees, including Subcommittee A of the NCI, which is … Continue reading 41-19 Sotomayor Named Inaugural Director of GW Cancer Center

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.